Health System

Biosimilars may need more time to devleop in the market.

For granulomatosis with microscopic polyangiitis in children.

Now approved for risk reductions in patients with type 2 diabetes mellitus.

Racemic substitutions for single-enantiomer drugs offer new opportunities for savings.

Biologic medicines could lower spending by $153 billion by 2023.

Will be part of the U.S.’s public health emergency medical supplies and pharmaceuticals.

Online pharmacy that discovered the impurity discontinues sales.

Monoclonal antibody for autoimmune and neurodegenerative disorders.

Caused by lower income, insurance status, higher prices, poor transportation, long distances.

Layoffs highlight increasing jobs problem. 

Monoclonal antibody shows potential for lupus nephritis treatment.

Programs shown to improve patient outcomes, reduce antibiotic resistance, and decrease healthcare costs.

23,600 cases across 29 states since 2016.

Fear, one's faith in the government, and likelihood of exposure are leading factors.

Oncologists recognize the potential of artificial intelligence (AI) in improving the quality of care and patient outcomes according to new research.

Indicated as part of a three-drug oral combination.

The 2018 oncology drug market had a record number of new treatments and continued a trend of growth.

NHE3 inhibitor administered as 50 mg oral tablets.

New medications and treatment guidelines

Patients are still allowed to take medicines as prescribed.

Fentanyl, oxymorphone, and hydrocodone face greatest cuts.

Eight pharmacy groups lauded a letter urging the Trump administration to reform direct and indirect remuneration (DIR) fees.

Current phase 3 studies investigative novel, preventative approaches.

Investigational oral MET kinase inhibitor from Merck.